Year Established: 1901
Revenues: $16,887 (-10%)
Loss: $1,555 (N/M)
R&D: $1,010 (-17%)
TOP SELLING DRUGS
|Bendeka||Leukaemia, chronic lymphocytic Non-Hodgkin lymphoma||$496||-23%|
|Methylphenidate Hydrochloride||Attention deficit disorder/hyperactivity||$412||-14%|
|Austedo||Huntington’s disease, Tardive dyskinesia||$412||102%|
Teva’s revenue fell 10% to $16.9 billion in 2019 mainly due to generic competition to COPAXONE, a decline in revenues from its U.S. generics business, and poor BENDEKA sales. Declines were partially offset by sales from AUSTEDO, AJOVY and QVAR in the U.S.
Teva bolstered its R&D presence in the U.S. with the purchase of three buildings in West Chester, PA, and with three other buildings Teva owns in the same corporate park, established a North America R&D campus. The site is focused primarily on biologics, a core area Teva continues to grow. The R&D campus houses clinical development and manufacturing processes for highly complex biologics. The campus also includes labs where preclinical and clinical testing is conducted to ensure the safety and effectiveness of new drugs.
In addition to infrastructure investment, Teva entered several biopharma research collaborations. Insilico Biotechnology and Teva entered an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceuticals.
Insilico’s Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms in combination with flexible process models and artificial intelligence to create optimized production processes using simulations.
The collaboration runs for three years and will be based at Insilico's sites in Stuttgart, Germany and at Teva’s West Chester location.
In another deal with Just Biotherapeutics, a design company focused on technologies for the manufacture of biotherapeutics, the companies will work to develop a high productivity biomanufacturing process with the goal of lowering the cost of manufacturing.
Also during the year, Teva teamed up with Genedata Biologics’ to use its workflow platform to streamline the identification, engineering, and characterization of novel biopharmaceuticals drugs.
Teva will use Genedata’s technology as the backbone system across its antibody discovery operations. In addition, the platform will enable a thorough assessment of a drug candidate’s developability profile and facilitate handovers to the Teva development and manufacturing organization.
Lastly, IONTAS, a provider of antibody discovery and optimization of human monoclonal antibody libraries, partnered with Teva to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.
IONTAS will initially apply its technologies to provide Teva with a panel of optimized antibodies against a defined target. Teva will have the option to enter into further optimization programs in the future. The agreement also includes options for the screening of biophysical properties suitable for developable antibodies.